Similar articles

• Can hypercalcaemia be avoided during oral calcitriol pulse therapy of secondary hyperparathyroidism in haemodialysis patients?

  Szotkiewicz M, Zdrojewski Z, Swima-Gillow A, Rutkowski B. Szotkiewicz M, et al. Nephrol Dial Transplant. 1995;10(9):1781-2. Nephrol Dial Transplant. 1995. PMID: 8559511 No abstract available.
• 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.

  Brandi L. Brandi L. Dan Med Bull. 2008 Nov;55(4):186-210. Dan Med Bull. 2008. PMID: 19232159 Review.
• [The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism].

  Kawabe M, Shimizu M, Takeuchi M, Matsunobu S, Hayama N, Iino Y, Hara K, Terashi A. Kawabe M, et al. Nihon Jinzo Gakkai Shi. 1992 Jul;34(7):807-11. Nihon Jinzo Gakkai Shi. 1992. PMID: 1479720 Japanese.
• Hyperparathyroidism in CAPD patients: therapy with pulse oral calcitriol.

  Juergensen PH, Finkelstein FO, Cooper K, Santacroce S, Kliger AS. Juergensen PH, et al. Adv Perit Dial. 1993;9:257-9. Adv Perit Dial. 1993. PMID: 8105938
• [Serum calcium concentration and the safety of vitamin D therapy].

  Ikeda Y, Takemoto F. Ikeda Y, et al. Clin Calcium. 2004 Sep;14(9):79-82. Clin Calcium. 2004. PMID: 15577116 Review. Japanese.